<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737722</url>
  </required_header>
  <id_info>
    <org_study_id>LAI2014-1</org_study_id>
    <nct_id>NCT02737722</nct_id>
  </id_info>
  <brief_title>Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus</brief_title>
  <official_title>A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lakewood-Amedex Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lakewood-Amedex Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or
      II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS
      score of 0 to 3 and DFI wound score of 1 to 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to run the cohorts in series with the completion of the first cohort
      before initiating the next dosing level. At all study visits the ulcer will be visually
      examined for any changes and photographed using the Aranz Medical Silhouette™ system that
      will calculate area and depth of the ulcer.

      In Arm 1, eligible subjects will be treated with a single application of Nu-3 or placebo in 4
      to 1 ratio to judge the initial safety of Nu-3 over a brief one (1) hour interval and 24-hr
      interval post application. Bisphosphocin Nu-3 will be applied topically to the chronic
      infected ulcer, covered with a non-abrasive bandage following the initial observation period.
      The subject will be released with verbal instructions to leave the bandage on the wound and
      return for a follow up visit within 24h ± 2h. At the follow up visit, the bandage will be
      removed, the ulcer visually examined and the subject cleared for the MAD Arm 2 based on the
      recommendation of the PI and absence of any SAEs.

      In Arm 2, eligible subjects which are those who have been approved by the PI after the Visit
      2 examination will be instructed in the proper application of bisphosphocin Nu-3. The
      subjects will be observed applying the first dose in the clinic to ensure compliance.
      Subjects will then be given a 7 day supply and sent home to continue treatment. Visit 4 or
      earlier in the case of any adverse events, subjects will return to the clinic for an
      examination, including visual examination of the ulcer, vital signs, adverse events, photo
      documentation, collection of a sample for microbiology and concomitant medication use. A
      final follow up visit will be scheduled +7 days after last dose of study medication (Day 15)
      for a complete examination as described above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)</measure>
    <time_frame>up to Day 15 (Visit 5)</time_frame>
    <description>The severity of each adverse event, as judged by the investigator, was graded according to the CTCAE v4.02. Treatment-emergent adverse events are defined as adverse events with onset times after dosing, or pre-existing adverse events that worsened during the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5</measure>
    <time_frame>Days 1, 2, 9, and 15 (Visits 2, 3, 4, and 5, respectively)</time_frame>
    <description>The microbiological response to bisphosphocin Nu-3 based on aerobic and anaerobic culture and sensitivity was determined by measuring the reduction of pathogenic bacteria following Nu-3 treatment. Each laboratory used their own standards to decide whether the cultures were normal or abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Diabetic Ulcer Severity Score (DUSS)</measure>
    <time_frame>Baseline and Day 15 (Visit 5)</time_frame>
    <description>Clinical response to bisphosphocin Nu-3 was determined by visual evaluation of ulcers, based on the Principal Investigator's judgement, following Nu-3 treatment. Ulcers were scored based on the DUSS. The following 4 parameters were scored as either 0 or 1. Palpable pedal pulses: presence, 0; absence, 1. Probing to the bone: no, 0; yes, 1. Location of ulcer: toe, 0; foot, 1. Number of ulcerations: single, 0; multiple, 1. The four parameter scores were summed to calculate a total score ranging from 0 to 4, with a higher score indicating increased severity. Baseline is defined as the last non-missing value obtained prior to receiving study drug. Change from Baseline is calculated as the post-Baseline value minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Diabetic Foot Ulcer Wound Infection Score</measure>
    <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
    <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. The Diabetic Foot Ulcer Wound Infection Score is a numerical scoring system comprised of 7 wound parameters. The score for each individual parameter is summed to calculate a total score, ranging from 0 (less severe infection) to 19 (more severe infection). Parameters are as follows: purulent discharge (0, absent; 3, present); non-purulent discharge (serious, sanguineous) (0, absent; 1, mild); other signs and symptoms of inflammation (erythema, induration, tenderness, pain; 0, none; 1, mild; 2, moderate; 3, severe); local warmth (relative to uninfected contralateral foot) (0, same; 1, mildly increased; 2, moderately increased; 3, severely increased).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Ulcer Area in the ITT Population</measure>
    <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
    <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the ITT Population</measure>
    <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
    <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Ulcer Area in the Per-Protocol Population</measure>
    <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
    <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population</measure>
    <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
    <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetic Foot Infections</condition>
  <arm_group>
    <arm_group_label>Bisphosphocin Nu-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisphosphocin Nu-3</intervention_name>
    <arm_group_label>Bisphosphocin Nu-3</arm_group_label>
    <other_name>Nu-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18 and 85.

          2. Voluntary written consent, given before performance of any clinical
             investigation-related procedure not part of standard medical care, and with the
             understanding that consent may be withdrawn at any time without prejudice to future
             medical care.

          3. Non-hospitalized ambulatory subjects suffering from Diabetes mellitus, Type I or II

          4. Diabetic foot ulcer(s) with a DUSS Score of 0 to 3

          5. Ulcerated area(s) of not more than two (2) ulcers between 0.5 to 6 cm2

          6. Any female of child bearing age must consent to use medically acceptable birth control
             for the duration of the study

          7. Female subjects must meet at least one of the following additional criteria:

               1. Surgically sterile with bilateral tubal ligation or hysterectomy.

               2. Post-menopausal for at least one year.

               3. If of child-bearing potential, practicing an acceptable method of birth control
                  for the duration of the clinical investigation as judged by the Investigator,
                  such as condoms, foams, jellies, diaphragm, intrauterine device or abstinence.

          8. Subjects willing to undergo pre-and post-clinical investigation blood collection,
             physical exams and laboratory investigations.

        Exclusion Criteria:

          1. A DUSS Score above 3.

          2. DUSS Probing to Bone = &quot;Yes&quot;

          3. An ulcer area(s) greater than 6 cm2 or more than two (2) ulcers

          4. Any subject that has received systemic or topical antibiotics within the last seven
             (7) days

          5. Any subject on topical antimicrobial treatment for their infected diabetic foot ulcer
             whose ulcer is responding to treatment

          6. Any subject that would be unable to follow the protocol procedures, safely monitor the
             infection status at home, and return for schedule visits

          7. Positive pregnancy test at Screening or Visit 2

          8. Active infection as demonstrated by temperature &gt; 37.5 oC and clinical features of
             active infection.

          9. Known immunosuppression or taking immunosuppressive agents including systemic
             steroids.

         10. History of severe co-morbidity with expected patient survival ≤ 6 months.

         11. Pregnancy or lactation

         12. Intake of investigational drugs within 28 days prior to enrollment.

         13. History of concurrent condition that, in the Investigator's opinion, would jeopardize
             the safety of the subject or compliance with the protocol.

         14. Likely inability to comply with the protocol or cooperate fully with the investigator
             and site personnel.

         15. Unwillingness or language barrier precluding adequate understanding of the trial
             procedure or cooperation with trial site personnel.

         16. Known or suspected active abuse of alcohol, narcotics or non-prescription drugs.

         17. Other planned surgical procedures within 30 days prior to or 30 days post-index
             procedure.

         18. Prior enrollment in this clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Kates, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lakewood-Amedex Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Journey Research, Inc.</name>
      <address>
        <city>Oldsmar</city>
        <state>Florida</state>
        <zip>34677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <results_first_submitted>July 5, 2019</results_first_submitted>
  <results_first_submitted_qc>October 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02737722/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02737722/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Overall, 48 participants were screened; 17 were screen failures and weren’t enrolled. One participant was enrolled but not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>2% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>2% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.6" spread="8.21"/>
                    <measurement group_id="B2" value="59.3" spread="8.41"/>
                    <measurement group_id="B3" value="60.5" spread="14.03"/>
                    <measurement group_id="B4" value="61.0" spread="6.54"/>
                    <measurement group_id="B5" value="59.0" spread="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Missing</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Diabetic Ulcer Wound Scoring System (DUSS) Score</title>
          <description>Ulcers were scored based on the DUSS. The following 4 parameters were scored as either 0 or 1. Palpable pedal pulses: presence, 0; absence, 1. Probing to the bone: no, 0; yes, 1. Location of ulcer: toe, 0; foot, 1. Number of ulcerations: single, 0; multiple, 1. The four parameter scores were summed to calculate a total score ranging from 0 to 4, with a higher score indicating increased severity. Baseline is defined as the last non-missing value obtained prior to receiving study drug. Data are collected in the Intent-to-Treat Population, comprised of all randomized participants.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" spread="0.35"/>
                    <measurement group_id="B2" value="1.25" spread="0.71"/>
                    <measurement group_id="B3" value="1.13" spread="0.64"/>
                    <measurement group_id="B4" value="1.00" spread="0.89"/>
                    <measurement group_id="B5" value="1.13" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Diabetic Foot Ulcer Wound Infection Score</title>
          <description>Baseline is defined as the last non-missing value obtained prior to receiving study drug. The score for each parameter is summed to calculate a total score, from 0 (less severe infection) to 19 (more severe infection). Parameters: purulent discharge (0, absent; 3, present); non-purulent discharge (serious, sanguineous) (0, absent; 1, mild); other signs/symptoms of inflammation (erythema, induration, tenderness, pain; 0, none; 1, mild; 2, moderate; 3, severe); local warmth (relative to uninfected contralateral foot) (0, same; 1, mildly increased; 2, moderately increased; 3, severely increased).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.38" spread="0.92"/>
                    <measurement group_id="B2" value="4.50" spread="1.60"/>
                    <measurement group_id="B3" value="4.63" spread="1.69"/>
                    <measurement group_id="B4" value="4.33" spread="1.31"/>
                    <measurement group_id="B5" value="4.47" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Ulcer Area in the Intent-to-Treat Population</title>
          <description>Baseline is defined as the last non-missing value obtained prior to receiving study drug.</description>
          <units>centimeters squared (cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="1.23"/>
                    <measurement group_id="B2" value="1.8" spread="1.54"/>
                    <measurement group_id="B3" value="1.9" spread="1.25"/>
                    <measurement group_id="B4" value="0.8" spread="0.20"/>
                    <measurement group_id="B5" value="1.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Ulcer Area in the Per-Protocol Population</title>
          <population>Data were collected in the Per-Protocol Population, comprised of all participants who met enrollment criteria, received all doses of investigational product as required by the protocol, and had no major protocol violations.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="1.36"/>
                    <measurement group_id="B2" value="1.8" spread="1.54"/>
                    <measurement group_id="B3" value="1.9" spread="1.25"/>
                    <measurement group_id="B4" value="0.8" spread="0.20"/>
                    <measurement group_id="B5" value="1.6" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)</title>
        <description>The severity of each adverse event, as judged by the investigator, was graded according to the CTCAE v4.02. Treatment-emergent adverse events are defined as adverse events with onset times after dosing, or pre-existing adverse events that worsened during the study.</description>
        <time_frame>up to Day 15 (Visit 5)</time_frame>
        <population>Safety Population: all participants administered any amount of investigational product</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Treatment-emergent Adverse Events as Graded According to the Common Terminology Criteria for Adverse Events v4.02 (CTCAE)</title>
          <description>The severity of each adverse event, as judged by the investigator, was graded according to the CTCAE v4.02. Treatment-emergent adverse events are defined as adverse events with onset times after dosing, or pre-existing adverse events that worsened during the study.</description>
          <population>Safety Population: all participants administered any amount of investigational product</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5</title>
        <description>The microbiological response to bisphosphocin Nu-3 based on aerobic and anaerobic culture and sensitivity was determined by measuring the reduction of pathogenic bacteria following Nu-3 treatment. Each laboratory used their own standards to decide whether the cultures were normal or abnormal.</description>
        <time_frame>Days 1, 2, 9, and 15 (Visits 2, 3, 4, and 5, respectively)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants. Only those participants with available data were analyzed. Microbiology results were not collected in the database for participants in the 0.1% cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Normal and Abnormal Cultures at Visits 2, 3, 4, and 5</title>
          <description>The microbiological response to bisphosphocin Nu-3 based on aerobic and anaerobic culture and sensitivity was determined by measuring the reduction of pathogenic bacteria following Nu-3 treatment. Each laboratory used their own standards to decide whether the cultures were normal or abnormal.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants. Only those participants with available data were analyzed. Microbiology results were not collected in the database for participants in the 0.1% cohort.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Visit 2), Normal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (Visit 2), Abnormal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Visit 3), Normal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 (Visit 3), Abnormal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (Visit 4), Normal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9 (Visit 4), Abnormal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (Visit 5), Normal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (Visit 5), Abnormal Culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1 (Visit 2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5152</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 1 (Visit 2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 2 (Visit 3)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 2 (Visit 3)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 9 (Visit 4)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 9 (Visit 4)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15 (Visit 5)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 15 (Visit 5)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3636</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Diabetic Ulcer Severity Score (DUSS)</title>
        <description>Clinical response to bisphosphocin Nu-3 was determined by visual evaluation of ulcers, based on the Principal Investigator's judgement, following Nu-3 treatment. Ulcers were scored based on the DUSS. The following 4 parameters were scored as either 0 or 1. Palpable pedal pulses: presence, 0; absence, 1. Probing to the bone: no, 0; yes, 1. Location of ulcer: toe, 0; foot, 1. Number of ulcerations: single, 0; multiple, 1. The four parameter scores were summed to calculate a total score ranging from 0 to 4, with a higher score indicating increased severity. Baseline is defined as the last non-missing value obtained prior to receiving study drug. Change from Baseline is calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Day 15 (Visit 5)</time_frame>
        <population>ITT Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Diabetic Ulcer Severity Score (DUSS)</title>
          <description>Clinical response to bisphosphocin Nu-3 was determined by visual evaluation of ulcers, based on the Principal Investigator's judgement, following Nu-3 treatment. Ulcers were scored based on the DUSS. The following 4 parameters were scored as either 0 or 1. Palpable pedal pulses: presence, 0; absence, 1. Probing to the bone: no, 0; yes, 1. Location of ulcer: toe, 0; foot, 1. Number of ulcerations: single, 0; multiple, 1. The four parameter scores were summed to calculate a total score ranging from 0 to 4, with a higher score indicating increased severity. Baseline is defined as the last non-missing value obtained prior to receiving study drug. Change from Baseline is calculated as the post-Baseline value minus the Baseline value.</description>
          <population>ITT Population. Only those participants with available data were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.64"/>
                    <measurement group_id="O2" value="-0.13" spread="0.35"/>
                    <measurement group_id="O3" value="-0.14" spread="0.69"/>
                    <measurement group_id="O4" value="-0.33" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.619</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Diabetic Foot Ulcer Wound Infection Score</title>
        <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. The Diabetic Foot Ulcer Wound Infection Score is a numerical scoring system comprised of 7 wound parameters. The score for each individual parameter is summed to calculate a total score, ranging from 0 (less severe infection) to 19 (more severe infection). Parameters are as follows: purulent discharge (0, absent; 3, present); non-purulent discharge (serious, sanguineous) (0, absent; 1, mild); other signs and symptoms of inflammation (erythema, induration, tenderness, pain; 0, none; 1, mild; 2, moderate; 3, severe); local warmth (relative to uninfected contralateral foot) (0, same; 1, mildly increased; 2, moderately increased; 3, severely increased).</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>ITT Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Diabetic Foot Ulcer Wound Infection Score</title>
          <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. The Diabetic Foot Ulcer Wound Infection Score is a numerical scoring system comprised of 7 wound parameters. The score for each individual parameter is summed to calculate a total score, ranging from 0 (less severe infection) to 19 (more severe infection). Parameters are as follows: purulent discharge (0, absent; 3, present); non-purulent discharge (serious, sanguineous) (0, absent; 1, mild); other signs and symptoms of inflammation (erythema, induration, tenderness, pain; 0, none; 1, mild; 2, moderate; 3, severe); local warmth (relative to uninfected contralateral foot) (0, same; 1, mildly increased; 2, moderately increased; 3, severely increased).</description>
          <population>ITT Population. Only those participants with available data were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="1.41"/>
                    <measurement group_id="O2" value="-1.50" spread="3.42"/>
                    <measurement group_id="O3" value="-2.86" spread="1.57"/>
                    <measurement group_id="O4" value="-3.00" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.432</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.715</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Ulcer Area in the ITT Population</title>
        <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>ITT Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Ulcer Area in the ITT Population</title>
          <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
          <population>ITT Population. Only those participants with available data were analyzed.</population>
          <units>centimeters squared (cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.62"/>
                    <measurement group_id="O2" value="-0.2" spread="0.77"/>
                    <measurement group_id="O3" value="-0.7" spread="0.68"/>
                    <measurement group_id="O4" value="-0.3" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the ITT Population</title>
        <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>ITT Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the ITT Population</title>
          <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
          <population>ITT Population. Only those participants with available data were analyzed.</population>
          <units>percentage of area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="34.41"/>
                    <measurement group_id="O2" value="10.8" spread="51.94"/>
                    <measurement group_id="O3" value="54.0" spread="36.67"/>
                    <measurement group_id="O4" value="41.0" spread="41.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Ulcer Area in the Per-Protocol Population</title>
        <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>Per-Protocol Population: all participants who met enrollment criteria, received all doses of investigational product as required by the protocol, and had no major protocol violations. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Ulcer Area in the Per-Protocol Population</title>
          <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
          <population>Per-Protocol Population: all participants who met enrollment criteria, received all doses of investigational product as required by the protocol, and had no major protocol violations. Only those participants with available data were analyzed.</population>
          <units>centimeters squared (cm^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.37"/>
                    <measurement group_id="O2" value="-0.2" spread="0.77"/>
                    <measurement group_id="O3" value="-0.7" spread="0.68"/>
                    <measurement group_id="O4" value="-0.3" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population</title>
        <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>Per-Protocol Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Percentage of Area Reduction for Ulcers in the Per-Protocol Population</title>
          <description>Change from Baseline is calculated as the post-Baseline value minus the Baseline value. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
          <population>Per-Protocol Population. Only those participants with available data were analyzed.</population>
          <units>percentage of area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="39.77"/>
                    <measurement group_id="O2" value="10.8" spread="51.94"/>
                    <measurement group_id="O3" value="54.0" spread="36.67"/>
                    <measurement group_id="O4" value="41.0" spread="41.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percentage of Participants With a Positive and Negative Global Clinical Impression of Microbiology Response</title>
        <description>Global impression of microbiological response was conducted by comparing culture value from Baseline to Visit 5 (Day 15). If culture values were not reported by the local laboratory, numerical values were assigned using the following criteria: heavy growth, 4+, moderate growth, 2+, scant, 1+, no bacteria, 0.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>Per-Protocol Population. Microbiology results were not collected in the database for participants in the 0.1% cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Positive and Negative Global Clinical Impression of Microbiology Response</title>
          <description>Global impression of microbiological response was conducted by comparing culture value from Baseline to Visit 5 (Day 15). If culture values were not reported by the local laboratory, numerical values were assigned using the following criteria: heavy growth, 4+, moderate growth, 2+, scant, 1+, no bacteria, 0.</description>
          <population>Per-Protocol Population. Microbiology results were not collected in the database for participants in the 0.1% cohort.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No apparent effect (negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apparent effect (positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Median Percent Change From Baseline in the Percentage Area Reduction for Ulcers in the Per-Protocol Population</title>
        <description>Percent change from Baseline is calculated as the [(post-Baseline value minus the Baseline value)/Baseline value] x 100. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
        <time_frame>Baseline; Day 15 (Visit 5)</time_frame>
        <population>Per-Protocol Population. Only those participants with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>2% Bisphosphocin Nu-3</title>
            <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change From Baseline in the Percentage Area Reduction for Ulcers in the Per-Protocol Population</title>
          <description>Percent change from Baseline is calculated as the [(post-Baseline value minus the Baseline value)/Baseline value] x 100. Baseline is defined as the last non-missing value obtained prior to receiving study drug. For participants who have more than one ulcer, the measurement of all ulcers were combined for analysis.</description>
          <population>Per-Protocol Population. Only those participants with available data were analyzed.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-13.5" upper_limit="87.9"/>
                    <measurement group_id="O2" value="13.1" lower_limit="-77.2" upper_limit="89.2"/>
                    <measurement group_id="O3" value="65.6" lower_limit="-4.0" upper_limit="90.1"/>
                    <measurement group_id="O4" value="29.9" lower_limit="-10.8" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.464</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Wilcoxon Rank Sum Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to Day 15 (Visit 5)</time_frame>
      <desc>Treatment-emergent adverse events, defined as adverse events with onset times after dosing, or pre-existing adverse events that worsened during the study, are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 0.1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>1% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 1% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>2% Bisphosphocin Nu-3</title>
          <description>Participants received a single topical administration of 2% Nu-3 solution in saline on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received a single topical administration of matching placebo on Day 1. Participants then applied the same dose twice a day for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Participants were enrolled into Cohorts 1, 2, and 3; Cohorts 4 and 5 were not enrolled because of challenges with enrolling participants. Additionally, Lakewood Amedex developed a gel formulation to be used for subsequent clinical studies.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Lakewood Amedex</organization>
      <phone>941 928 7774</phone>
      <email>poconnor@lakewoodamedex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

